2V9Q

First and second Ig domains from human Robo1

2V9Q の概要

• エントリーDOI: 10.2210/pdb2v9q/pdb
• 関連するPDBエントリー: 2V9R 2V9S 2V9T
• 分子名称: ROUNDABOUT HOMOLOG 1, MERCURY (II) ION (3 entities in total)
• 機能のキーワード: proto-oncogene, differentiation, phosphorylation, disease mutation, neuronal development, immunoglobulin domain, chemotaxis, neurogenesis, glycoprotein, transmembrane, robo1, membrane, receptor, ig domain, roundabout, developmental protein
• 由来する生物種: HOMO SAPIENS (HUMAN)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 23988.90

構造登録者

Morlot, C.,Cusack, S.,McCarthy, A.A. (登録日: 2007-08-25, 公開日: 2007-09-25, 最終更新日: 2024-10-23)

主引用文献

Morlot, C.,Thielens, N.M.,Ravelli, R.B.G.,Hemrika, W.,Romijn, R.A.,Gros, P.,Cusack, S.,Mccarthy, A.A.
Structural Insights Into the Slit-Robo Complex.
Proc.Natl.Acad.Sci.USA, 104:14923-, 2007

PubMed Abstract: Slits are large multidomain leucine-rich repeat (LRR)-containing proteins that provide crucial guidance cues in neuronal and vascular development. More recently, Slits have been implicated in heart morphogenesis, angiogenesis, and tumor metastasis. Slits are ligands for the Robo (Roundabout) receptors, which belong to the Ig superfamily of transmembrane signaling molecules. The Slit-Robo interaction is mediated by the second LRR domain of Slit and the two N-terminal Ig domains of Robo, but the molecular details of this interaction and how it induces signaling remain unclear. Here we describe the crystal structures of the second LRR domain of human Slit2 (Slit2 D2), the first two Ig domains of its receptor Robo1 (Ig1-2), and the minimal complex between these proteins (Slit2 D2-Robo1 Ig1). Slit2 D2 binds with its concave surface to the side of Ig1 with electrostatic and hydrophobic contact regions mediated by residues that are conserved in other family members. Surface plasmon resonance experiments and a mutational analysis of the interface confirm that Ig1 is the primary domain for binding Slit2. These structures provide molecular insight into Slit-Robo complex formation and will be important for the development of novel cancer therapeutics.

PubMed: 17848514
DOI: 10.1073/PNAS.0705310104

実験手法

X-RAY DIFFRACTION (2.5 Å)